Triphasil-21

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Triphasil-21

Triphasil-21 is a brand-name, prescription-only (Rx) combined oral contraceptive pill, widely known as a form of birth control. It is manufactured by Pfizer and contains two synthetic female hormones: levonorgestrel (a progestin) and ethinyl estradiol (an estrogen).

Its key feature is its triphasic design. This means the dose of the active hormones changes three times throughout the 21 active tablets, a design intended to closely mimic the hormonal fluctuations of a woman's natural menstrual cycle.

Property Description
Active Ingredients Levonorgestrel and Ethinyl Estradiol
Form Oral tablets
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of pregnancy
Origin Synthetic (man-made hormones)

Triphasil-21 is indicated for the prevention of pregnancy. The medication is part of the class of medicines that works primarily by reliably inhibiting ovulation—preventing the release of an egg from the ovary. It also makes changes to the cervical mucus and the lining of the uterus.

The medication is structured as a 21-day regimen. Each pack contains 21 active pills, followed by a 7-day pill-free interval, during which withdrawal bleeding typically occurs.

What side effects are possible with Triphasil-21?

Triphasil-21 (levonorgestrel/ethinyl estradiol) is associated with a spectrum of officially documented adverse reactions, which regulatory agencies classify by frequency and physiological system. This information helps define the safety profile, distinguishing between commonly reported, less severe events and rare, critical complications.

Adverse Reactions and Frequencies

Official regulatory documents classify non-serious reactions into frequency categories:

  • Very Common Reactions: These include headache, nausea or vomiting, breast pain or tenderness, and irregular uterine bleeding (breakthrough bleeding).
  • Common Reactions: These are documented to occur in 1% to 10% of users and may include migraine, dizziness, abdominal pain, acne, and fluid retention.

Serious Safety Considerations

The most significant serious risks documented in regulatory materials relate to thromboembolic events, which are rare but critical. These include an increased risk of Venous Thromboembolism (VTE), which can manifest as deep vein thrombosis or pulmonary embolism, and Arterial Thromboembolism (ATE), encompassing stroke and myocardial infarction. Other rare, serious adverse reactions include the development of benign liver tumors (Hepatic Adenomas).

Safety Patterns and Restrictions

Regulatory documents highlight that the risk of serious thromboembolic events is highest during the first year of use or when restarting the medication after a break of four weeks or more. Furthermore, the official label defines specific constraints based on pre-existing conditions and lifestyle factors:

Constraint Factor Safety Consideration
Smoking and Age Use is contraindicated in women over 35 years old who smoke due to a markedly increased risk of serious cardiovascular events.
Pre-existing Conditions Contraindicated in individuals with a history of thromboembolic disorders, specific vascular diseases, or severe hepatic impairment.
Time of Exposure Irregular bleeding is most frequent during the initial months of use.

Overdose and Emergency Response

The official regulatory guidance for a potential overdose of Triphasil-21 (levonorgestrel/ethinyl estradiol) classifies the event based on the typically low acute toxicity of its hormonal components. Ingestion of a substantial overdose is officially stated as not likely to be life-threatening.

Documented Clinical Manifestations

The documented manifestations of overdose are typically minor and focus on expected physiological responses. These signs primarily include gastrointestinal effects such as nausea and vomiting, as well as other reported symptoms like headache, dizziness, abdominal pain, and breast tenderness. A characteristic sign is the potential onset of withdrawal bleeding in females, which may occur within several days following the overdose. Regulatory documents indicate that overdose symptoms may present in both adults and children. Furthermore, official information explicitly states that an overdose does not terminate an existing pregnancy.

Emergency Action and Management

Regulatory authorities mandate that if an overdose is suspected, the individual must seek medical help right away. The required immediate step is to call a Poison Control Center for specific guidance on next steps. Management of the condition is officially limited to symptomatic and supportive treatment, as the prescribing information confirms that no specific antidote is known. Hospital monitoring, including the assessment of vital signs and possible blood and urine tests, may be required as part of the supportive care protocol.

Therapeutic Uses of Triphasil-21

What Triphasil-21 Treats: Main Uses and Benefits

Triphasil-21 (levonorgestrel/ethinyl estradiol) is applied when appropriate as part of symptomatic management across key reproductive and cyclical symptom domains. Its therapeutic focus is on achieving specific health outcomes and offering supportive symptomatic relief. The medication’s primary therapeutic use is the prevention of pregnancy in females of reproductive potential, a use relevant in situations with significant discomfort.

Therapeutic Scope and Key Benefits

Triphasil-21 is commonly used to help with multiple symptom-driven clinical presentations. The medication is relevant for easing severe menstrual cramping (dysmenorrhea) and assisting with the management of excessively heavy menstrual flow (menorrhagia), and is commonly used to help with cycle regularity. It also helps address related symptom clusters that may become intense or disruptive, such as the pronounced mood changes linked to severe PMDD and the skin manifestations of moderate acne.

The practical benefit centers on providing support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable. This is particularly relevant when symptoms create noticeable functional strain or interfere with routine activities.

“This medication is commonly used to help patients seeking both a method of pregnancy prevention and supportive relief from disruptive monthly symptoms.”


Quick Fact: Relief for Cyclical Discomfort The medication is considered relevant for managing symptoms that may create noticeable functional strain, particularly in conditions involving episodic manifestations of discomfort.

Regulatory References

  1. FDA Prescribing Information for its components

Eligibility and Restrictions for Use

Who can and cannot use Triphasil-21?

Eligibility for Triphasil-21 (levonorgestrel/ethinyl estradiol) is defined by official regulatory documentation, which permits use for females of reproductive potential seeking pregnancy prevention. However, the medicine is subject to an extensive list of absolute contraindications primarily related to cardiovascular, hepatic, and hormonal cancer risks.

Contraindicated Populations (Must Not Use)

Triphasil-21 is contraindicated and must not be used by women with:

  • A history of or current diagnosis of thromboembolic disorders (e.g., DVT, PE, stroke) or coronary artery disease.
  • Known or suspected breast cancer or other estrogen-sensitive cancers.
  • Liver tumors (benign or malignant), active liver disease, or severe cirrhosis.
  • Uncontrolled hypertension or diabetes with vascular involvement.
  • A history of migraine with focal neurological symptoms (e.g., migraine with aura).
  • Undiagnosed abnormal uterine bleeding or known or suspected pregnancy.

Age and Physiological Restrictions

Use is not indicated for females before menarche (onset of menstruation) or for postmenopausal women. The medicine is not recommended for use in lactating women (breastfeeding) as it may decrease milk production. Furthermore, use is prohibited in females over 35 years of age who smoke.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Triphasil-21 (levonorgestrel/ethinyl estradiol) is primarily defined by pharmacokinetic changes related to the CYP450 enzyme system and specific regulatory prohibitions. These interactions are documented to alter the plasma concentration of the hormones or the levels of co-administered medicines, potentially impacting treatment outcomes.

Formal Contraindications

Co-administration is formally prohibited with certain Hepatitis C drug combinations, specifically those containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir), glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir. This is due to the documented risk of significant Alanine Aminotransferase (ALT) elevations. Additionally, co-administration with oral Tranexamic Acid is contraindicated due to a pharmacodynamic synergistic interaction that increases the documented risk of thrombotic events.

Metabolic Interactions Affecting Hormone Exposure

  • Enzyme Inducers (Decreased Exposure): Strong enzyme inducers, such including certain anticonvulsants (e.g., phenytoin, carbamazepine), the antibacterial rifampicin, and the herbal product St. John’s Wort, accelerate hormone metabolism via CYP3A4 induction. This pharmacokinetic interaction decreases hormone plasma concentrations, which is officially documented to result in reduced contraceptive effectiveness and a risk of breakthrough bleeding.
  • Enzyme Inhibitors (Increased Exposure): Strong CYP3A4 inhibitors (e.g., certain antifungals like ketoconazole) may increase the plasma concentrations of the active hormones, potentially raising the incidence of hormone-related adverse reactions.

Interactions Affecting Co-administered Drugs

The ethinyl estradiol component is documented to inhibit the clearance of other medicines (e.g., lamotrigine, theophylline). This interaction causes a significant decrease in lamotrigine plasma concentration due to increased clearance and may lead to an increase in the concentration of other medicines metabolized by CYP1A2 and CYP2C19.

Mechanism of Action

Central Suppression of the HPO Axis

This primary mechanism involves the drug's synthetic hormones acting as agonists on their respective estrogen and progestin receptors. This activity sends a strong negative feedback signal to the hypothalamus and pituitary gland, resulting in the near-total suppression of the release of Gonadotropin-Releasing Hormone ( GnRH), Follicle-Stimulating Hormone ( FSH), and Luteinizing Hormone ( LH). The profound suppression of FSH prevents the maturation of ovarian follicles, while the suppression of LH prevents the necessary LH surge. This action leads directly to the inhibition of ovulation (anovulation), a principal physiological consequence of HPO axis suppression.


Peripheral Modulation of the Cervix and Endometrium

This secondary mechanism focuses on the progestin component acting on local tissues, resulting in direct structural and secretory changes. In the cervix, this hormonal agonism rapidly increases the viscosity and cellularity of the mucus, and simultaneously alters the endometrial lining, causing it to develop asynchronously. The resulting changes in the cervical mucus create a physical barrier that impedes sperm motility and transit , and the altered endometrial structure renders the lining less receptive. These peripheral effects function as secondary physiological mechanisms that influence the drug's overall mechanistic profile.

Dosage and Administration Information

How to Use Triphasil-21

Triphasil-21 is administered through the oral route as a daily tablet, following a strict cyclic regimen. The proper use of this medication is based on standardized instructions to ensure the correct triphasic hormonal delivery pattern.

Official Administration Schedule

The standard regimen involves taking one active tablet daily for 21 consecutive days, followed by a 7-day hormone-free interval. The medication is designed for long-term, repetitive use, with new cycles beginning immediately after the 7-day interval is complete.

Feature Detail
Administration Route Oral (swallowing).
Dosing Frequency One tablet daily, at the same time each day.
Cyclic Pattern 21 days on (active tablets) followed by 7 days off (pill-free).

Procedural Instructions

The triphasic design requires strict adherence to the sequential order of the 21 active tablets, which contain three different hormone strength combinations: 6 brown, then 5 white, then 10 light-yellow. Taking the tablets out of sequence violates the established triphasic pattern. Intake is often recommended to be taken consistently after the evening meal or at bedtime.

The subsequent pack must always be initiated on the same day of the week as the very first dose was taken. In certain scenarios, such as initiation after the recommended starting day, a non-hormonal back-up method is specified for the initial seven consecutive days of active tablet administration. Furthermore, initiation should not occur until 28 days postpartum for non-lactating individuals.

Recent Clinical Evidence

Recent Clinical Evidence: Triphasil-21

Research on Potential Action

Research has been conducted to investigate the potential action of the triphasic combination of levonorgestrel and ethinyl estradiol. These initial investigations focused on basic biological pathways. Preliminary studies examined the compound's characteristics.


Clinical Study Findings

Primary Efficacy Endpoints

Clinical trials generally focused on two primary measures. First, investigators sought to determine if pregnancy rates were affected based on standard outcome measures. Second, assessments were made regarding the potential effect on menstrual cycle regularity and bleeding patterns.

  • Study Design: The majority of robust evidence comes from randomized, open-label, or placebo-controlled trials (RCTs) of varying durations.
  • Observed Outcomes: Research explored the time-course of potential changes in symptoms related to the menstrual cycle. Studies also evaluated patterns of unscheduled bleeding in trial participants.

Safety and Tolerability Profiles

Safety data has been collected across numerous Phase I, II, and III trials. In the studies, observed adverse events most frequently included mild nausea, breast tenderness, and headache. These events were generally reported to decrease after the first few cycles of use.

  • Vascular Risk: Studies have also considered the compound in populations with certain vascular risk factors, and evidence in these specific groups remains limited. Certain studies reviewed potential interactions with common antimicrobial agents and anticonvulsants.

Key Studies & References

  1. NICE Guideline NG10: Contraception

Frequently Asked Questions (FAQ)

Common questions about Triphasil-21 (FAQ)


Q: Can certain antibiotics make Triphasil-21 less effective?

Regulatory documents indicate that certain drug classes, specifically strong enzyme inducers, may affect how Triphasil-21 works. This class includes the antibacterial rifampicin and some anti-seizure medications. This pharmacokinetic interaction is documented to potentially result in reduced contraceptive effectiveness due to lowered hormone levels.


Q: Is there a known interaction between Triphasil-21 and St. John's Wort?

Yes, official product information lists the herbal product St. John's Wort as a potential interacting substance. It is classified as a strong enzyme inducer, which can accelerate the way the body breaks down the hormones in Triphasil-21. This process is documented to result in a reduction in contraceptive effectiveness.


Q: What should be done if I miss one of the active pills in a Triphasil-21 pack?

Official guidelines provide detailed instructions for managing a missed active tablet. These protocols are specific, depending on the timing, the number of pills missed, and the week of the cycle. Official guidelines emphasize the importance of following the specific Patient Information Leaflet for the exact protocols, as back-up contraception may be required.


Q: Does vomiting or severe diarrhea impact the effectiveness of Triphasil-21?

Official guidance notes that if severe diarrhea or vomiting occurs shortly after taking the pill, the amount of hormone absorbed into the body may be reduced. If this happens for a specified duration, the medication's effectiveness may be impacted. Regulatory documentation indicates that back-up contraception may be required if this occurs for a specified duration.


Q: What is the difference between Triphasil-21 and a monophasic pill?

The key difference is the hormone dose. A triphasic pill like Triphasil-21 changes the dosage of its active hormones three times throughout the 21 active tablets. In contrast, a monophasic pill contains a consistent, unchanging dose of hormones in every active tablet.


Q: Is Triphasil-21 used for purposes other than preventing pregnancy?

While the medication is formally indicated by major regulatory bodies for the prevention of pregnancy, official patient information leaflets in some regions state that it may also be used to help with symptoms like menstrual cycle irregularity, cramps, and acne.


Q: Can Triphasil-21 affect mood or emotional well-being?

Yes, regulatory labeling addresses emotional well-being in its safety information. Mental depression is listed as an adverse reaction, and official guidance advises monitoring for significant changes in depression symptoms, particularly for individuals with a history of depression.


Q: Is weight gain a common side effect described for Triphasil-21?

Regulatory documentation lists changes in weight as an adverse reaction. However, its frequency of occurrence is not specifically documented in the common or very common categories, which usually represent adverse events experienced by 1% or more of users.


Q: Are there any common changes to menstruation patterns while using Triphasil-21?

Yes, changes to bleeding patterns are common. Irregular uterine bleeding (spotting or breakthrough bleeding) is classified in official documents as a very common reaction, particularly during the initial months of use. Clinical studies explored patterns of unscheduled bleeding in trial participants.


Q: Is nausea a typical temporary side effect when first starting Triphasil-21?

Nausea is classified as a very common reaction listed in regulatory documents. Clinical study findings noted that observed adverse events, including nausea, were generally reported to decrease after the first few cycles of use.


Q: Can Triphasil-21 cause changes in skin appearance, like acne?

Yes, acne is listed in official regulatory documents as a common reaction associated with the use of the medicine, meaning it may be experienced by 1% to 10% of users.


Q: Are there warnings about changes in vision while using Triphasil-21?

Official precautions advise that contact lens wearers who develop visual changes or changes in lens tolerance should have an eye assessment. Additionally, a history of migraine with focal neurological symptoms is listed as a contraindication for use.


Q: What kind of vision changes are occasionally reported with combination pills like Triphasil-21?

Regulatory documents cite a need for assessment for visual changes in contact lens wearers. However, specific types of vision changes are generally not listed as common adverse events in the regulatory prescribing information.


Q: Is it common to have breast tenderness when starting Triphasil-21?

Breast pain or tenderness is classified as a very common reaction in official safety information. Clinical evidence indicates that this and other observed adverse events were generally reported to decrease after the first few cycles of use.


Q: Can Triphasil-21 affect cholesterol levels?

Yes, official warnings mention the potential for adverse effects on lipid metabolism. Regulatory guidelines indicate that assessment of glucose levels and consideration of alternative contraceptive methods are relevant for women with uncontrolled dyslipidemias (abnormal lipid levels).


Q: Are there known instances of Triphasil-21 interfering with lab test results?

Yes, regulatory guidance states that certain blood tests may be affected by the medication. Official guidance states that patients should share this information with their healthcare provider or lab personnel before lab tests.


Q: How quickly does Triphasil-21 start working after beginning the first pack?

Contraceptive reliance is officially stated not to be placed on the tablets until after the first seven consecutive days of active tablet administration are complete. Official guidance therefore requires a non-hormonal back-up method during that initial period, depending on when the first pill was taken.


Q: Are there any studies focusing on the long-term use of Triphasil-21?

The medication is designed for long-term, repetitive use. Safety data has been collected across numerous Phase I, II, and III clinical trials of varying durations. However, the official prescribing information does not define a maximum duration for its use.


Q: Do I need to use another method when taking Triphasil-21 for the first time?

Yes, regulatory protocols specify that if the medication is not started on the recommended day, a non-hormonal back-up method of contraception is specified for the initial seven consecutive days of active tablet administration to ensure adequate effectiveness.


Q: Will Triphasil-21 cause my period to completely stop?

The medication may cause amenorrhea (absence of menstruation), which is addressed in regulatory warnings and precautions. Regulatory documents mention that if amenorrhea persists, other causes are generally subject to evaluation.


Q: How long does it usually take for menstruation to return to normal after stopping Triphasil-21?

Clinical evidence suggests that discontinuing the medication does not delay the return to fertility after cessation of use. Most individuals experience the resumption of their normal menstrual cycle relatively quickly.


Q: Does taking Triphasil-21 make it harder to get pregnant in the future?

Studies have not found evidence that the use of this type of combined oral contraceptive results in a delay or difficulty in achieving pregnancy after the medication is discontinued. Fertility generally returns rapidly after stopping the medication.


Q: Does Triphasil-21 protect against sexually transmitted infections (STIs)?

No, regulatory labeling clarifies that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections (STIs). A barrier method, like condoms, is needed for STI protection.


Q: Can Triphasil-21 be taken with common dietary supplements or vitamins?

The official interaction profile primarily documents interactions with prescription medicines and specific herbal products that induce or inhibit CYP450 enzymes (how the body processes drugs). Interactions with common vitamins or general dietary supplements are not typically documented in the official regulatory product information.


Q: Can Triphasil-21 be used to regulate an irregular cycle?

In addition to preventing pregnancy, official patient information in some regions states that this medication may be used to help control irregularities in the frequency and flow of the menstrual cycle. This is a common non-contraceptive effect.

How should Triphasil-21 be stored and disposed of?

How to Store and Dispose of Triphasil-21

Triphasil-21 (levonorgestrel/ethinyl estradiol) must be stored according to official regulatory conditions to maintain stability.


Storage Requirements

The tablets must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should be kept in its original blister pack and carton.

  • Do not freeze the medicine or store it in areas subject to excessive heat or dampness.
  • It is mandatory to keep Triphasil-21 out of the reach and sight of children.

Disposal Instructions

Official instructions for disposal state that unused or expired medicine must not be thrown into household waste or flushed down the toilet. Patients should consult with a pharmacist or healthcare provider to find a drug take-back program or follow local regulations for discarding pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Triphasil-21 found in:

A-Z Index: